Q4 2024 Earnings Call Transcript February 6, 2025 Illumina, Inc. misses on earnings expectations. Reported EPS is $0.91 EPS, ...

Q4 2024 Management View CEO Jacob Thaysen highlighted the transformative progress Illumina made in 2024, emphasizing its strategic roadmap targeting high single-digit revenue growth by 2027. He noted ...

The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $366,099, and 4 are calls, amounting to ...

Shares of Illumina (NASDAQ: ILMN) were falling on Friday. The company's stock was down by as much as 11.4% early in the session, and was still off by 8.7% as of 2:38 p.m. ET. At that time ...

The U.S. tariffs on China include a broad 10% levy on imported goods. China’s response was more targeted, with 15% tariffs on ...

Analysts said the move comes amid rising trade tensions with the U.S. and as Illumina faces stiff competition in China’s ...

Illumina Inc (ILMN) reports steady revenue growth and strategic advancements, while addressing competitive pressures and geopolitical risks.

Illumina recently launched the MiSeq i100 and MiSeq i100 Plus Systems, two powerful, compact benchtop sequencers that incorporate more than 140 invention disclosures and 60 patent families.

The genomics industry is set for growth due to advancements in personalized medicine, diagnostics, and biotech innovations.

After China placed Illumina on a government watchlist this week, in response to new tariffs imposed by the Trump ...

Patrick B Donnelly, an analyst from Citi, maintained the Hold rating on Illumina (ILMN – Research Report). The associated price target remains ...

Illumina has struggled to boost sales and consistently deliver positive earnings. Its Q4 report was largely a disappointment, and management's 2025 guidance came in below Wall Street's ...